8 January 2026
VBB advises Adjuvant Global Health Technologies on investment in Phoenix Biosciences
1 min read
VBB has dvised private investment fund Adjuvant Global Health Technologies (Adjuvant) on its investment in Phoenix Biosciences.
In the context of the Belgian pre-pack bankruptcy procedure relating to the distressed Univercells group, new corporate vehicle Phoenix Biosciences has acquired certain assets of Univercells subsidiary Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Adjuvant was a shareholder in the Univercells group and, alongside fellow shareholders, has contributed to a capital raise for Phoenix Biosciences.
The VBB team comprised partner Caroline DAOUT, counsel Virginie Lescot and associate Jens Westerwoudt.
->
News & insights
1 min
read
read
Briefings
Court of Justice of European Union Clarifies Scope of Officinal Formula Exemption Under EU Medicinal Product Law
25 March 2026
1 min
read
read
Briefings
European Commission publishes draft Industrial Accelerator Act: What to expect?
17 March 2026
1 min
read
read
Briefings
Belgian Competition Authority Investigates AutoScout24 Platform for Possible Abuse of Dominance
13 March 2026
1 min
read
read
Briefings
EU General Court Annuls Anti-Circumvention Extension and rejects Commission’s Broad View of “Assembly Operations”
6 March 2026
2 min
read
read
Briefings
Belgium - Publication of Rules of Procedure of Committee for Borderline Products for Human Use
4 March 2026
1 min
read
read
Briefings
Belgian Competition Authority Carries out Dawn Raids on Suppliers of Road Signage and Street Furniture
3 March 2026
2 min
read
read
Briefings
Belgian Competition Authority Investigates Google for Possible Abuse of Dominance in Online Advertising Sector
27 February 2026
